Literature DB >> 23238011

A new "brew" of MALT1 inhibitors.

Ryan M Young1, Louis M Staudt.   

Abstract

The activated B cell-like (ABC) subtype of diffuse large B cell lymphoma (DLBCL) is an aggressive lymphoma that is addicted to NF-κB signaling through the CARD11-BCL10-MALT1 complex. In this issue of Cancer Cell, Nagel and colleagues and Fontan and colleagues describe MALT1 inhibitors suitable for clinical use that are selectively toxic to this malignancy.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Year:  2012        PMID： 23238011      PMCID： PMC4053348          DOI： 10.1016/j.ccr.2012.11.011

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  10 in total

1.  Oncogenically active MYD88 mutations in human lymphoma.

Authors:  Vu N Ngo; Ryan M Young; Roland Schmitz; Sameer Jhavar; Wenming Xiao; Kian-Huat Lim; Holger Kohlhammer; Weihong Xu; Yandan Yang; Hong Zhao; Arthur L Shaffer; Paul Romesser; George Wright; John Powell; Andreas Rosenwald; Hans Konrad Muller-Hermelink; German Ott; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; J R Cook; Denny D Weisenburger; Wing C Chan; Louis M Staudt
Journal:  Nature       Date:  2010-12-22       Impact factor: 49.962

2.  Oncogenic CARD11 mutations in human diffuse large B cell lymphoma.

Authors:  Georg Lenz; R Eric Davis; Vu N Ngo; Lloyd Lam; Thaddeus C George; George W Wright; Sandeep S Dave; Hong Zhao; Weihong Xu; Andreas Rosenwald; German Ott; Hans Konrad Muller-Hermelink; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Richard I Fisher; Wing C Chan; Louis M Staudt
Journal:  Science       Date:  2008-03-06       Impact factor: 47.728

3.  MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo.

Authors:  Lorena Fontan; Chenghua Yang; Venkataraman Kabaleeswaran; Laurent Volpon; Michael J Osborne; Elena Beltran; Monica Garcia; Leandro Cerchietti; Rita Shaknovich; Shao Ning Yang; Fang Fang; Randy D Gascoyne; Jose Angel Martinez-Climent; J Fraser Glickman; Katherine Borden; Hao Wu; Ari Melnick
Journal:  Cancer Cell       Date:  2012-12-11       Impact factor: 31.743

Review 4.  MALT1 protease: a new therapeutic target in B lymphoma and beyond?

Authors:  Linda M McAllister-Lucas; Mathijs Baens; Peter C Lucas
Journal:  Clin Cancer Res       Date:  2011-08-25       Impact factor: 12.531

5.  Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL.

Authors:  Daniel Nagel; Stefani Spranger; Michelle Vincendeau; Michael Grau; Silke Raffegerst; Bernhard Kloo; Daniela Hlahla; Martin Neuenschwander; Jens Peter von Kries; Kamyar Hadian; Bernd Dörken; Peter Lenz; Georg Lenz; Dolores J Schendel; Daniel Krappmann
Journal:  Cancer Cell       Date:  2012-12-11       Impact factor: 31.743

6.  A loss-of-function RNA interference screen for molecular targets in cancer.

Authors:  Vu N Ngo; R Eric Davis; Laurence Lamy; Xin Yu; Hong Zhao; Georg Lenz; Lloyd T Lam; Sandeep Dave; Liming Yang; John Powell; Louis M Staudt
Journal:  Nature       Date:  2006-03-29       Impact factor: 49.962

7.  Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.

Authors:  R Eric Davis; Vu N Ngo; Georg Lenz; Pavel Tolar; Ryan M Young; Paul B Romesser; Holger Kohlhammer; Laurence Lamy; Hong Zhao; Yandan Yang; Weihong Xu; Arthur L Shaffer; George Wright; Wenming Xiao; John Powell; Jian-Kang Jiang; Craig J Thomas; Andreas Rosenwald; German Ott; Hans Konrad Muller-Hermelink; Randy D Gascoyne; Joseph M Connors; Nathalie A Johnson; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Wyndham H Wilson; Jan Delabie; Erlend B Smeland; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; J R Cook; Dennis D Weisenburger; Wing C Chan; Susan K Pierce; Louis M Staudt
Journal:  Nature       Date:  2010-01-07       Impact factor: 49.962

8.  Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells.

Authors:  Uta Ferch; Bernhard Kloo; Andreas Gewies; Vera Pfänder; Michael Düwel; Christian Peschel; Daniel Krappmann; Jürgen Ruland
Journal:  J Exp Med       Date:  2009-10-19       Impact factor: 14.307

9.  Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma.

Authors:  Stephan Hailfinger; Georg Lenz; Vu Ngo; Anita Posvitz-Fejfar; Fabien Rebeaud; Montserrat Guzzardi; Eva-Maria Murga Penas; Judith Dierlamm; Wing C Chan; Louis M Staudt; Margot Thome
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-06       Impact factor: 11.205

10.  Congenital B cell lymphocytosis explained by novel germline CARD11 mutations.

Authors:  Andrew L Snow; Wenming Xiao; Jeffrey R Stinson; Wei Lu; Benjamin Chaigne-Delalande; Lixin Zheng; Stefania Pittaluga; Helen F Matthews; Roland Schmitz; Sameer Jhavar; Stefan Kuchen; Lela Kardava; Wei Wang; Ian T Lamborn; Huie Jing; Mark Raffeld; Susan Moir; Thomas A Fleisher; Louis M Staudt; Helen C Su; Michael J Lenardo
Journal:  J Exp Med       Date:  2012-11-05       Impact factor: 14.307
  10 in total
  11 in total

1.  US National Cancer Institute-China Collaborative Studies on Chinese Medicine and Cancer.

Authors:  Libin Jia; Hongsheng Lin; Joost Oppenheim; O M Zack Howard; Jie Li; Huiting Fan; Zhizheng Zhao; William Farrar; Ying Zhang; Nancy Colburn; Matthew R Young; Weidong Li; David Newman; Barry R O'Keefe; John Beutler; Jikai Liu; Xiaojiang Hao; Xiaosheng Yang; Tengfei Ji; Jeffrey D White
Journal:  J Natl Cancer Inst Monogr       Date:  2017-11-01

2.  MALT1 is not alone after all: identification of novel paracaspases.

Authors:  Paco Hulpiau; Yasmine Driege; Jens Staal; Rudi Beyaert
Journal:  Cell Mol Life Sci       Date:  2015-09-16       Impact factor: 9.261

Review 3.  Diffuse large B-cell lymphoma-treatment approaches in the molecular era.

Authors:  Mark Roschewski; Louis M Staudt; Wyndham H Wilson
Journal:  Nat Rev Clin Oncol       Date:  2013-11-12       Impact factor: 66.675

4.  Secondary Metabolites from the Fungus Dictyosporium sp. and Their MALT1 Inhibitory Activities.

Authors:  Trong D Tran; Brice A P Wilson; Curtis J Henrich; Louis M Staudt; Lauren R H Krumpe; Emily A Smith; Jarrod King; Karen L Wendt; Alberto M Stchigel; Andrew N Miller; Robert H Cichewicz; Barry R O'Keefe; Kirk R Gustafson
Journal:  J Nat Prod       Date:  2019-01-02       Impact factor: 4.050

Review 5.  Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma.

Authors:  M Ponzoni; S Issa; T T Batchelor; J L Rubenstein
Journal:  Ann Oncol       Date:  2013-11-20       Impact factor: 32.976

6.  Novel CARD11 Mutations in Human Cutaneous Squamous Cell Carcinoma Lead to Aberrant NF-κB Regulation.

Authors:  Stephen A Watt; Karin J Purdie; Nicoline Y den Breems; Michelle Dimon; Sarah T Arron; Angela T McHugh; Dylan J Xue; Jasbani H S Dayal; Charlotte M Proby; Catherine A Harwood; Irene M Leigh; Andrew P South
Journal:  Am J Pathol       Date:  2015-07-26       Impact factor: 4.307

Review 7.  The CARD11-BCL10-MALT1 (CBM) signalosome complex: Stepping into the limelight of human primary immunodeficiency.

Authors:  Stuart E Turvey; Anne Durandy; Alain Fischer; Shan-Yu Fung; Raif S Geha; Andreas Gewies; Thomas Giese; Johann Greil; Bärbel Keller; Margaret L McKinnon; Bénédicte Neven; Jacob Rozmus; Jürgen Ruland; Andrew L Snow; Polina Stepensky; Klaus Warnatz
Journal:  J Allergy Clin Immunol       Date:  2014-08       Impact factor: 10.793

8.  Identification of MALT1 as both a prognostic factor and a potential therapeutic target of regorafenib in cholangiocarcinoma patients.

Authors:  Chun-Nan Yeh; Yu-Chan Chang; Yeu Su; Dennis Shin-Shian Hsu; Chi-Tung Cheng; Ren-Chin Wu; Yi-Hsiu Chung; Kun-Chun Chiang; Ta-Sen Yeh; Meng-Lun Lu; Chun-Yu Liu; Peter Mu-Hsin Chang; Ming-Han Chen; Chi-Ying F Huang; Michael Hsiao; Ming-Huang Chen
Journal:  Oncotarget       Date:  2017-12-08

9.  Mucosa-Associated Lymphoid Tissue 1 Is an Oncogene Inducing Cell Proliferation, Invasion, and Tumor Growth via the Upregulation of NF-κB Activity in Human Prostate Carcinoma Cells.

Authors:  Ke-Hung Tsui; Kang-Shuo Chang; Hsin-Ching Sung; Shu-Yuan Hsu; Yu-Hsiang Lin; Chen-Pang Hou; Pei-Shan Yang; Chien-Lun Chen; Tsui-Hsia Feng; Horng-Heng Juang
Journal:  Biomedicines       Date:  2021-03-03

10.  The Antitumor Effect of Caffeic Acid Phenethyl Ester by Downregulating Mucosa-Associated Lymphoid Tissue 1 via AR/p53/NF-κB Signaling in Prostate Carcinoma Cells.

Authors:  Kang-Shuo Chang; Ke-Hung Tsui; Shu-Yuan Hsu; Hsin-Ching Sung; Yu-Hsiang Lin; Chen-Pang Hou; Pei-Shan Yang; Chien-Lun Chen; Tsui-Hsia Feng; Horng-Heng Juang
Journal:  Cancers (Basel)       Date:  2022-01-06       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.